AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22941038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20298784 — intervention group
Group type: COMPARATOR
Intervention: 1.0 microg alfacalcidol
Number of subjects: 59
Study 20298784 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg eldecalcitol
Number of subjects: 59
Study 20298784 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microg eldecalcitol
Number of subjects: 59
Study 20298784 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-1.0 microg eldecalcitol
Number of subjects: 59
Study 18796622 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-to-creatinine ratio (ACR)
Number of subjects: 3188
Study 18796622 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartiles of ACR
Number of subjects: 3188
Study 18796622 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR levels below microalbuminuria range
Number of subjects: 3188
Study 18796622 — intervention group
Group type: COMPARATOR
Intervention: DPP intervention groups (placebo, lifestyle, metformin)
Number of subjects: 3188
Study 16816561 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (metronidazole plus erythromycin antenatally and metronidazole plus ampicillin intrapartum)
Number of subjects: 1510
Study 16816561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1510
Study 12645827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1,000 microg/day
Number of subjects: 281
Study 12645827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 10990474 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7711219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant
Number of subjects: 362
Study 7711219 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine Varnish
Number of subjects: 362
Study 7711219 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 362
Study 2523645 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 mg or 5 mg twice daily)
Number of subjects: 80
Study 2523645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 356497 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg) and Triamterene (50 mg) with possible addition of Methyldopa (up to 2 g daily)
Number of subjects: 349
Study 356497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study 356497 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and Triamterene
Number of subjects: 349
Study 31848551 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (40 g daily)
Number of subjects: 90
Study 31848551 — intervention group
Group type: COMPARATOR
Intervention: Casein protein (40 g daily)
Number of subjects: 90
Study 31288093 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional academic course with clinical ultrasound training (Group A)
Number of subjects: 40
Study 31288093 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound simulator training before clinical ultrasound training (Group B)
Number of subjects: 40
Study 31288093 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received learning and training sessions on OUS after initial assessments
Number of subjects: 40
Study 28711736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose psilocybin (0.160 mg/kg)
Number of subjects: 58
Study 28711736 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose psilocybin (0.215 mg/kg)
Number of subjects: 58
Study 28711736 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (both doses)
Number of subjects: 58
Study 28711736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 25876527 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous walking for 30 min
Number of subjects: 25
Study 25876527 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated walking (three 10 min bouts)
Number of subjects: 25
Study 25876527 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 25
Study 23596237 — intervention group
Group type: EXPERIMENTAL
Intervention: Antituberculosis agents
Number of subjects: 90
Study 21209030 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + fortified milk
Number of subjects: 180
Study 21209030 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 180
Study 21209030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk
Number of subjects: 180
Study 21209030 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 180
Study 18310963 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta (dose: 6 MU, daily for 4, 6, or 8 weeks)
Number of subjects: 111
Study 16517183 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI scanner noise (85 dB)
Number of subjects: 24
Study 16517183 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise (85 dB)
Number of subjects: 24
Study 16517183 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no noise)
Number of subjects: 24
Study 14680546 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 2.5 mg/day (n = 7)
Number of subjects: 15
Study 14680546 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 100 mg/day (n = 8)
Number of subjects: 15
Study 11110233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily
Number of subjects: 120
Study 11110233 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene 0.005% ointment twice daily
Number of subjects: 120
Study 11110233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene plus corticosteroid regimen
Number of subjects: 120
Study 11110233 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene group
Number of subjects: 120
Study 8642525 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% hypertonic saline solution
Number of subjects: 5
Study 8642525 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 5
Study 8366876 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg saperconazole per day for 7 days
Number of subjects: 4
Study 8366876 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg saperconazole per day for 7 days
Number of subjects: 4
Study 8366876 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg saperconazole per day for 14 days
Number of subjects: 4
Study 2889281 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month regimen of daily isoniazid plus rifampicin, supplemented by streptomycin twice a week for the first 6 months
Number of subjects: 51
Study 2889281 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month regimen of daily isoniazid plus rifampicin, supplemented by streptomycin twice a week for the first 6 months
Number of subjects: 51
Study 2889281 — intervention group
Group type: COMPARATOR
Intervention: 6-month regimen
Number of subjects: 51
Study 2889281 — intervention group
Group type: COMPARATOR
Intervention: 9-month regimen
Number of subjects: 51
Study 29793564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate Partial Pulpotomy (PP)
Number of subjects: 25
Study 29793564 — intervention group
Group type: COMPARATOR
Intervention: Formocresol Pulpotomy (FP)
Number of subjects: 25
Study 27824741 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextrose distention
Number of subjects: 176
Study 27824741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluorescein
Number of subjects: 176
Study 27824741 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phenazopyridine
Number of subjects: 176
Study 27824741 — intervention group
Group type: COMPARATOR
Intervention: Saline distention
Number of subjects: 176
Study 24781851 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle change intervention
Number of subjects: 100
Study 22525443 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMS) given at twice the recommended dietary allowance (RDA)
Number of subjects: 847
Study 22525443 — intervention group
Group type: COMPARATOR
Intervention: Six-multivitamin (MV) supplement given in one RDA as the 'standard of care'
Number of subjects: 847
Study 22525443 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMS)
Number of subjects: 847
Study 22525443 — intervention group
Group type: COMPARATOR
Intervention: Six-multivitamin (MV) supplement
Number of subjects: 847
Study 21243936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual peach immunotherapy (standardized peach extract quantified in mass units of Pru p 3) for 6 months
Number of subjects: 56
Study 21243936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18506403 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically-assisted rapid maxillary expansion (SRME)
Number of subjects: 31
Study 16457397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 4895
Study 16457397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4895
Study 12580687 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived infrequent parental monitoring
Number of subjects: 217
Study 10477639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (human) (FSH)
Number of subjects: 47
Study 10477639 — intervention group
Group type: COMPARATOR
Intervention: Thrombin-soaked gelatin sponge (TSG)
Number of subjects: 47
Study 8934061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomegestrol subdermal contraceptive implant (Uniplant)
Number of subjects: 240
Study 8934061 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine contraceptive device (CuT 380A)
Number of subjects: 240
Study 1877516 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 181
Study 1877516 — intervention group
Group type: COMPARATOR
Intervention: Caffeinated coffee (control)
Number of subjects: 181
Study 1877516 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (discontinuation)
Number of subjects: 181
Study 6401357 — intervention group
Group type: EXPERIMENTAL
Intervention: flexed position
Number of subjects: 17
Study 6401357 — intervention group
Group type: EXPERIMENTAL
Intervention: extended position
Number of subjects: 17
Study 6401357 — intervention group
Group type: EXPERIMENTAL
Intervention: upright position
Number of subjects: 17
Study 30837021 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye tracking measure
Number of subjects: 20
Study 30837021 — intervention group
Group type: EXPERIMENTAL
Intervention: No neglect symptoms
Number of subjects: 20
Study 30837021 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined egocentric and allocentric neglect
Number of subjects: 20
Study 30837021 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocentric or egocentric neglect
Number of subjects: 20
Study 29698019 — intervention group
Group type: EXPERIMENTAL
Intervention: Similar Age Mixed Gender (SAMG) exercise group
Number of subjects: 627
Study 29698019 — intervention group
Group type: EXPERIMENTAL
Intervention: Similar Age Same Gender (SASG) exercise group
Number of subjects: 627
Study 29698019 — intervention group
Group type: COMPARATOR
Intervention: Standard Mixed Age Mixed Gender (MAMG) exercise group
Number of subjects: 627
Study 26493304 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg with morphine 5 mg
Number of subjects: 12
Study 26493304 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 60 mg with placebo
Number of subjects: 12
Study 24906437 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER (50-250 mg twice daily)
Number of subjects: 50
Study 24906437 — intervention group
Group type: COMPARATOR
Intervention: Morphine SR (20-140 mg/day)
Number of subjects: 50
Study 24906437 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER
Number of subjects: 50
Study 22854406 — intervention group
Group type: COMPARATOR
Intervention: Pure ß-carotene in oil (0.5 mg)
Number of subjects: 68
Study 22854406 — intervention group
Group type: EXPERIMENTAL
Intervention: Golden Rice ß-carotene (0.6 mg)
Number of subjects: 68
Study 22854406 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach ß-carotene (1.4 mg)
Number of subjects: 68
Study 19736632 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 treatment for 18 consecutive days
Number of subjects: 62
Study 19736632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 62
Study 17763050 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician discussion of substance use and addiction behaviors with patients
Number of subjects: 0
Study 17763050 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician discussion of substance use and health promotion counseling
Number of subjects: 0
Study 17763050 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician discussion of substance use and addiction
Number of subjects: 0
Study 17763050 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician discussion of substance use and addiction behaviors
Number of subjects: 0
Study 17763050 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction-oriented practice style
Number of subjects: 0
Study 17763050 — intervention group
Group type: EXPERIMENTAL
Intervention: Addressing substance use and smoking
Number of subjects: 0
Study 15673130 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 0
Study 15673130 — intervention group
Group type: COMPARATOR
Intervention: Current blood pressure management targets
Number of subjects: 0
Study 11806476 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral-B D17 power toothbrush
Number of subjects: 110
Study 11806476 — intervention group
Group type: COMPARATOR
Intervention: ADA reference manual toothbrush
Number of subjects: 110
Study 9488498 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine infusion (0.16 microg/kg/min) after 30 minutes of pretreatment with low L-NMMA
Number of subjects: 9
Study 9488498 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine infusion (0.16 microg/kg/min) after 30 minutes of pretreatment with high L-NMMA
Number of subjects: 9
Study 9488498 — intervention group
Group type: COMPARATOR
Intervention: Histamine infusion alone (no L-NMMA pretreatment)
Number of subjects: 9
Study 7851263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified conventional treatment
Number of subjects: 96
Study 7851263 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment
Number of subjects: 96
Study 3386328 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (three intravenous dose levels)
Number of subjects: 4
Study 3386328 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 4
Study 31785390 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐ACT (porcine-derived collagen-augmented chondrogenesis technique)
Number of subjects: 100
Study 31785390 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (control group)
Number of subjects: 100
Study 30274344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-based diet
Number of subjects: 95
Study 28969702 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourcing intervention for HIV test promotion
Number of subjects: 1280
Study 28969702 — intervention group
Group type: COMPARATOR
Intervention: Conventional campaigns
Number of subjects: 1280
Study 28969702 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourcing intervention
Number of subjects: 1280
Study 26428734 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum HY7714 (1 × 10(10) CFU/day)
Number of subjects: 110
Study 26428734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 23352812 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilting embryo culture system (TECS)
Number of subjects: 32
Study 23352812 — intervention group
Group type: COMPARATOR
Intervention: Control static culture system
Number of subjects: 32
Study 21168015 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting + reduction annuloplasty
Number of subjects: 75
Study 19633578 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinutrient fortifier added to human milk (n=19)
Number of subjects: 39
Study 19633578 — intervention group
Group type: COMPARATOR
Intervention: Human milk alone (n=20)
Number of subjects: 39
Study 16969617 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidopexy (SH)
Number of subjects: 50
Study 16969617 — intervention group
Group type: COMPARATOR
Intervention: Ferguson hemorrhoidectomy (FH)
Number of subjects: 50
Study 12751804 — intervention group
Group type: EXPERIMENTAL
Intervention: Active oddball task (rats)
Number of subjects: 0
Study 12751804 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive single-stimulus task (humans)
Number of subjects: 0
Study 12751804 — intervention group
Group type: EXPERIMENTAL
Intervention: P3 component (rats)
Number of subjects: 0
Study 12751804 — intervention group
Group type: EXPERIMENTAL
Intervention: P3 component (humans)
Number of subjects: 0
Study 12751804 — intervention group
Group type: COMPARATOR
Intervention: Comparison of P3 components between species
Number of subjects: 0
Study 11097105 — intervention group
Group type: EXPERIMENTAL
Intervention: 1995 knowledge of lipid values
Number of subjects: 1000
Study 11097105 — intervention group
Group type: EXPERIMENTAL
Intervention: 1995 belief in hyperlipidaemia as a cause of CHD
Number of subjects: 1000
Study 11097105 — intervention group
Group type: EXPERIMENTAL
Intervention: 1995 belief in reduction of hyperlipidaemia reducing cardiovascular risk
Number of subjects: 1000
Study 11097105 — intervention group
Group type: EXPERIMENTAL
Intervention: 1995 belief in reduction of hypertension reducing cardiovascular risk
Number of subjects: 1000
Study 11097105 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of doctors knowing about smoking habits
Number of subjects: 1000
Study 11097105 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of doctors knowing about drinking habits
Number of subjects: 1000
Study 9075669 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 225 mg/day
Number of subjects: 36
Study 9075669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8416267 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose isotretinoin (0.5 mg per kilogram per day)
Number of subjects: 59
Study 8416267 — intervention group
Group type: COMPARATOR
Intervention: Beta carotene (30 mg per day)
Number of subjects: 59
Study 2429631 — intervention group
Group type: EXPERIMENTAL
Intervention: surgery + DTIC
Number of subjects: 1058
Study 2429631 — intervention group
Group type: EXPERIMENTAL
Intervention: surgery + BCG
Number of subjects: 1058
Study 2429631 — intervention group
Group type: EXPERIMENTAL
Intervention: surgery + DTIC + BCG
Number of subjects: 1058
Study 2429631 — intervention group
Group type: EXPERIMENTAL
Intervention: surgery + poly‐U‐A
Number of subjects: 1058
Study 2429631 — intervention group
Group type: EXPERIMENTAL
Intervention: surgery + vinblastine/bleomycine/cisplatinum
Number of subjects: 1058
Study 2429631 — intervention group
Group type: COMPARATOR
Intervention: surgery
Number of subjects: 1058
Study 30796508 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg phytosomal curcumin (Curserin®: 200 mg curcumin, 120 mg phosphatidylserine, 480 mg phosphatidylcholine and 8 mg piperine from Piper nigrum L. dry extract) for 8 weeks
Number of subjects: 80
Study 30796508 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg phytosomal curcumin (Curserin®)
Number of subjects: 80
Study 30796508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 29406428 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) for 24 weeks
Number of subjects: 426
Study 29406428 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) and antiretroviral therapy (ART)
Number of subjects: 426
Study 26523653 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (160 mg daily for 3 weeks)
Number of subjects: 10
Study 26523653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 26523653 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 10
Study 23733256 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year supervised lifestyle intervention
Number of subjects: 83
Study 23733256 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine lifestyle counselling)
Number of subjects: 83
Study 23154393 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Number of subjects: 238
Study 23154393 — intervention group
Group type: COMPARATOR
Intervention: No axillary dissection
Number of subjects: 238
Study 20142024 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NT-proBNP levels measured in pg/mL using the Elecsys proBNP assay (Roche)
Number of subjects: 3562
Study 20142024 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of baseline characteristics
Number of subjects: 3562
Study 17969365 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 0
Study 15659491 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg oral gefitinib daily continuously
Number of subjects: 40
Study 15659491 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral gefitinib daily continuously
Number of subjects: 40
Study 15659491 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study 12516646 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading of machined-surface Brånemark implants in healed bone
Number of subjects: 36
Study 12516646 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading of machined-surface Brånemark implants in fresh extraction sites
Number of subjects: 36
Study 12516646 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostheses installed in fresh extraction sites
Number of subjects: 36
Study 12516646 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional loading of implants
Number of subjects: 36
Study 12516646 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal bone level measurements
Number of subjects: 36
Study 9704783 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of initial hospital stay > 48 hours
Number of subjects: 4323
Study 9704783 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care visits
Number of subjects: 4323